HTA

Also known as: Health Technology Assessment

The systematic evaluation of a medicine's clinical and cost-effectiveness for reimbursement decisions.

Definition

Health Technology Assessment (HTA) is the structured evaluation of a health intervention's clinical effectiveness, cost-effectiveness, and broader social/ethical impact. HTA bodies — NICE (UK), G-BA/IQWiG (Germany), HAS (France), CADTH (Canada), PBAC (Australia), TLV (Sweden) — drive reimbursement decisions in their jurisdictions.

See also

• NICE — The UK body that decides whether the NHS will reimburse a drug, based on cost-effectiveness.
• PBAC — The Australian committee that decides which medicines are listed on the publicly-funded PBS.
• ICER (cost) — The cost-per-extra-QALY a treatment delivers compared to the standard of care.

Other commercial terms

• Biosimilar
• Generic drug
• QALY
• NICE TA
• ICER (cost)
• WAC